Preclinically, anti-Ang2 agents have largely been studied in the context of primary tumor growth, often demonstrating additive anti-angiogenic effects when combined with VEGF pathway inhibitors (Brown et al, 2010; Doppalapudi et al, 2010; Koh et al, 2010; Huang et al, 2011; Mazzieri et al, 2011; Schaefer et al, 2011; Holopainen et al, 2012; Leow et al, 2012). The gene discussed is ANGPT2; the disease is neoplasm.